Inconex Xl (Tolterodine Tartrate)

Inconex Xl, an antimuscarinic agent, is used to treat conditions related to bladder overactivity.

• Overactive bladder: reduces involuntary detrusor contractions and improves bladder capacity.
• Urinary frequency: decreases the number of daily voids.
• Urgency: lessens the sudden, compelling urge to void.
• Urge urinary incontinence: helps prevent involuntary leakage associated with urgency.

• Tolterodine tartrate acts as a competitive antagonist at muscarinic M2 and M3 receptors in the detrusor muscle of the bladder. By blocking these receptors, it diminishes acetylcholine‑mediated contractions, thereby reducing involuntary bladder activity and increasing functional bladder capacity without significantly affecting sphincter tone.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dry mouth: reduced salivary secretion causing a feeling of thirst.
• Constipation: slowed gastrointestinal motility leading to hard stools.
• Blurred vision: transient changes in visual acuity.
• Headache: mild to moderate head discomfort.
• Urinary retention: difficulty initiating or completing urination.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Tachycardia: rapid heart rate requiring medical attention.
• Angle‑closure glaucoma: acute eye pain and visual disturbance.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Persistent urinary retention: may necessitate catheterisation.

Before initiating therapy, consider patient‑specific factors and monitor for potential complications.

• Renal function assessment: adjust use in patients with impaired clearance.
• Monitor for urinary retention: especially in those with bladder outlet obstruction.
• Avoid in narrow‑angle glaucoma: anticholinergic effect may precipitate an attack.
• Use caution in the elderly: increased sensitivity to anticholinergic side effects.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Tolterodine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase tolterodine levels.
• Strong CYP3A4 inducers (e.g., rifampin): reduce therapeutic effect.
• Other anticholinergic agents: additive anticholinergic burden.

Moderate Interactions (Monitor Closely):\n- Diuretics: may exacerbate urinary frequency.

• Antihypertensives: possible additive blood pressure lowering.
• Digoxin: monitor for altered plasma concentrations.